• ReconRecon

    Recon: Elizabeth Holmes found guilty of four counts of fraud; Another big Paxlovid deal

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US More than 1 million Americans were diagnosed with COVID over the long holiday weekend ( NPR ) ( Reuters ) Elizabeth Holmes is found guilty of four counts of fraud ( NYT ) ( POLITICO ) The Epic Rise and Fall of Elizabeth Holmes ( NYT ) Pfizer carries pandemic momentum into 2022, scoring another huge Paxlovid deal with the US ( Fierce ) CDER, CBER Approve Total...
  • RoundupsRoundups

    Asia-Pacific Roundup: TGA asks drugmakers to mitigate cybersecurity weakness amid ‘active malicious exploitation’

    Australia’s Therapeutic Goods Administration (TGA) has asked drugmakers and other stakeholders to detect and mitigate a cybersecurity vulnerability. TGA made the request after learning of “widespread and active malicious exploitation” of the critical vulnerability in an open-source logging library.   Developers across multiple industries use Apache's Log4j to track activity in their software applications and online services. The log serves as a journal of activity that...
  • Regulatory NewsRegulatory News

    FDA proposes 180-day transition before terminating COVID-19 EUAs, enforcement policies

    The US Food and Drug Administration (FDA) is proposing to give medical device makers 180-days’ notice before terminating emergency use authorizations (EUAs) and phasing out its enforcement policies for medical devices issued during the COVID-19 public health emergency (PHE).   The transition plan comes in the form of two draft guidances issued in late December, in which FDA explains that the transition policies are intended to “prepare manufacturers and other stakehold...
  • Regulatory NewsRegulatory News

    ICH releases revised Q9 guideline to improve risk assessments

    The International Council for Harmonization (ICH) issued a revision of the Q9 guideline that aims to address the shortcomings of the current guideline. The goal of the revision is to provide “more scientific and robust applications of quality risk management principles (QRM)” leading to “fewer quality defects and recalls” and reduced costs for the pharmaceutical industry, according to an ICH business plan .   The ICH Q9(R1) guideline was published on the European Me...
  • ReconRecon

    Recon: FDA clears Pfizer booster for 12- to 15-year-olds; Teva found liable in New York opioid trial

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US The FDA clears booster shots for 12- to 15-year olds ( NYTimes ) ( STAT ) ( Reuters ) ( WashingtonPost ) FDA authorizes new Merck Covid-19 pill despite scientists' concerns on its mechanism of action ( Endpoints ) FDA authorizes the first at-home pills from Pfizer to treat Covid-19 ( Endpoints ) Interval between Moderna COVID-19 vaccine second shot and booster...
  • Feature ArticlesFeature Articles

    December’s Regulatory Focus: Advertising, promotion, and labeling

    Feature articles during December focused on advertising, promotion, and labeling (APL), examining regulatory review of advertising on streaming media, the role of the regulatory A&P professional, the importance of metrics in APL, and the regulatory outlook for telehealth A&P. Also included is the second part of a two-part series on EU regulation of herbal products, examining quality, safety and efficacy, and postmarket surveillance.   Last year this time, the issue co-...
  • RoundupsRoundups

    Euro Roundup: Commission acts to stop Brexit from disrupting supply of medicines

    The European Commission has set out how it plans to stop Brexit from disrupting the supply of drugs in certain markets, most notably Northern Ireland. The plan builds on the proposal the Commission made in October as part of the multiple rounds of negotiations with the United Kingdom.   Under parts of the Brexit agreement designed to avoid a hard border on Ireland, Northern Ireland, which is part of the UK, is subject to European Union regulations. The situation has ...
  • RoundupsRoundups

    FDA Approvals Roundup: Apretude, Vyvgart, Tezspire

    A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA). New approvals  Apretude cleared for HIV pre-exposure prevention  Viiv’s Apretude (cabotegravir extended-release injectable suspension) has been  approved  for use in at-risk adults and adolescents for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV.  Approval of Apretude was based on safety and efficacy findings from two randomized, dou...
  • Feature ArticlesFeature Articles

    The regulatory outlook for telehealth advertising and promotion

    The global pandemic has increased the use of telehealth and accelerated its acceptance into mainstream healthcare. However, the regulatory landscape has yet to fully catch up with this expansion of telehealth. This article discusses some of the potential advertising and promotional regulatory implications as telehealth becomes a mainstay in the ever-evolving healthcare sector. The article explores the advertising and promotion of off-label drug prescriptions by telehealth ...
  • Feature ArticlesFeature Articles

    The role of metrics in regulatory advertising and promotion

    Metrics can provide valuable information about business operations and, if used appropriately, can provide insight into key process efficiencies and challenges. This article discusses the role of metrics in regulatory advertising and promotion and how they can be used to increase efficiencies for the promotional review process.   Introduction The review of promotional materials and their associated processes may vary through a content’s lifecycle, from conception t...
  • Feature ArticlesFeature Articles

    Regulatory advertising & promotion: Bringing value beyond the day-to-day

    While the primary goal of the clinical development team is to obtain product approval, companies must have a broader vision that supports the complete product lifecycle. Experts in regulatory advertising and promotion (A&P) have a detailed knowledge of the US Food and Drug Administration (FDA) requirements for product promotion. Beyond supporting the promotional review process, the unique skill set of regulatory A&P should be applied to other critical activities, including...
  • RAPS' LatestRAPS' Latest

    Need the fundamentals of pharma or device regulations? RAPS’ product-sector books have it covered

    RAPS’ Fundamentals of Regulatory Affairs series of books has been a trusted reference for regulatory professionals for more than two decades since the publication of the first edition of Fundamentals of US Regulatory Affairs . Over the years, more titles have been added to the series, covering not only US regulations, but also those in the EU as well as important international standards. Originally, each fundamentals book covered the full regulatory landscape in a coun...